Primary Record
Dutasteride
Note: Only for scientific research or as raw materials for production.
- In stock
- 9,891 g
- Purity
- 99.8 %
- CAS
- 164656-23-9
Compound Identifiers & Properties
- CAS
- 164656-23-9
- PubChem CID
- 6918296
- SMILES
- C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NC4=C(C=CC(=C4)C(F)(F)F)C(F)(F)F)CC[C@@H]5[C@@]3(C=CC(=O)N5)C
- Canonical SMILES
- C[C@]12C=CC(=O)N[C@@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](C(=O)Nc3cc(C(F)(F)F)ccc3C(F)(F)F)CC[C@@H]12
Names & Synonyms
- Dutasteride
- Avodart
- Avolve
- 164656-23-9
- Duastride
- Duagen
- veltride
- Dutasterida
- dutasteridum
- Dutasterid
- Avidart
- Duprost
- Avidart;
- Avodart;
- Dutagen;
- Dutasteride [USAN]
- Dutasteride CRS
- Avolve;
- Duagen;
- Avodart (TN)
- Dutas;
- GG-745
- Avidart (TN)
- Duprost (TN)
- Dutagen (TN)
- Avodart, Dutasteride
- Avolve (TN)
- Duagen (TN)
- Dutas (TN)
- Dutasteride (Standard)
- O0J6XJN02I
- RefChem:57229
- UNII-O0J6XJN02I
- DUTASTERIDE [MI]
- C27H30F6N2O2
- DUTASTERIDE [INN]
- DUTASTERIDE [JAN]
- GI-198745
- DTXSID8046452
- GG 745
- D0A9YA
- DUTASTERIDE [VANDF]
- Dutasteride(forbidden drug)
- AC1OCF98
- Dutasteride [USAN:INN:BAN]
- GI 198745
- SCHEMBL5903
- JWJOTENAMICLJG-QWBYCMEYSA-N
- DUTASTERIDE [MART.]
- GG745
- MFCD00937869
- CHEMBL1200969
- DTXCID6026452
- DUTASTERIDE [USP-RS]
- DUTASTERIDE [WHO-DD]
- Dutasteride (JAN/USP/INN)
- NSC-740477
- CHEBI:521033
- Dutasteride (JAN/USAN/INN)
- Dutasteride [USAN:INN:JAN]
- JALYN COMPONENT DUTASTERIDE
- GTPL7457
- orb1308434
- Dutasteride - Bio-X trade mark
- NSC-759880
- SCHEMBL29454739
- Dutasteride, >=98% (HPLC)
- AOB5568
- DUTASTERIDE [ORANGE BOOK]
- G04CB02
- Dutasteride for system suitability
- BCPP000248
- DUTASTERIDE [EP MONOGRAPH]
- Dutasteride CRS (Y0001598)
- GI198745
- GLXC-06659
- DUTASTERIDE [USP MONOGRAPH]
- GI-198745X
- 745, GG
- BCP02344
- EX-A1952
- MSK15349
- ZINC3932831
- Tox21_112199
- BDBM50340481
- EBC-11281
- HY-13613R
- NP3151
- NSC740477
- s1202
- 2-Hydroxy-4-trifluoromethylpyrimidine
- AKOS015920136
- AKOS015924431
- Dutasteride for system suitability CRS
- MSK15349-100A
- ACN-046785
- BCP9000630
- C27-H30-F6-N2-O2
- CCG-269904
- CID6918296
- CS-1542
- CS-O-30894
- DB01126
- FD22629
- GS-3565
- MSK15349-1000A
- NSC 740477
- NSC 759880
- RL02115
- 4-Bromo-1-isopropylpyridin-2(1H)-one
- CID:6918296
- NCGC00164571-01
- BD164398
- BR-72895
- HY-13613
- SC-08812
- SID:283537524
- (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide
- AB1009276
- J677.498I
- CAS-164656-23-9
- D5973
- ST24026289
- (5alpha,17beta)-N-(2,5-Bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide
- B-2151
- D03820
- Dutasteride Solution in Acetonitrile, 100ug/mL
- EN300-124223
- J10036
- 1H-Indeno[5,4-f]quinoline-7-carboxamide, N-[2,5-bis(trifluoromethyl)phenyl]-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)-
- AB01274774-01
- AB01274774_02
- alpha,alpha,alpha,alpha',alpha',alpha'-Hexafluoro-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxy-2',5'-xylidide
- Dutasteride Solution in Acetonitrile, 1000ug/mL
- 656D239
- A810580
- C108373
- Q424760
- (4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-(2,5-Bis(trifluoromethyl)phenyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
- BRD-K30373883-001-02-8
- Dutasteride for System Suitability CRS (Y0001603)
- (1S,3aS,3bS,5aR,9aR,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide
- D000068538
- Z1558504346
- Dutasteride, European Pharmacopoeia (EP) Reference Standard
- N-[2,5-bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide
- 17beta-N-(2,5-bis(trifluoromethyl))phenyl-carbamoyl-4-aza-5alpha-androst-1-en-3-one
- Dutasteride, United States Pharmacopeia (USP) Reference Standard
- (1S,2R,7R,10S,11S,14S,15S)-N-[2,5-bis(trifluoromethyl)phenyl]-2,15-dimethyl-5-oxo-6-azatetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-3-ene-14-carboxamide
- (4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-[2,5-bis(trifluoromethyl)phenyl]-4a,6a-dimethyl-2-oxo-1H,2H,4aH,4bH,5H,6H,6aH,7H,8H,9H,9aH,9bH,10H,11H,11aH-indeno[5,4-f]quinoline-7-carboxamide
- (5|A,17|A)-N-{2,5-Bis(trifluoromethyl)phenyl}-3-oxo-4-azaandrost-l-ene-17-carboxamide
- 17-beta-N-[2,5-Bis(trifluoromethyl)phenyl]carbamoyl-4-aza-5-alpha-androst-1-en-3-one
- 17beta-[[2,5-Bis(trifluoromethyl)phenyl]carbamoyl]-4-aza-5alpha-androsta-1-ene-3-one
- Dutasteride for system suitability, European Pharmacopoeia (EP) Reference Standard
- N-(2,5-bis(trifluoromethyl)phenyl)-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide
- (1S,2R,7R,10S,11S,14S,15S)-N-(2,5-bis(trifluoromethyl)phenyl)-2,15-dimethyl-5-oxo-6-azatetracyclo(8.7.0.0^(2,7).0^(11,15))heptadec-3-ene-14-carboxamide
- (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-(2,5-bis(trifluoromethyl)phenyl)-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno(5,4-f)quinoline-1-carboxamide
- (4ar,4bs,6as,7s,9as,9bs,11ar)-n-[2,5-bis(trifluoromethyl)phenyl]-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-1h-indeno[5,4-f]quinoline-7-carboxamide
- (4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-[2,5-Bis(trifluoromethyl)phenyl]-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
- (5-alpha,17-beta)-N-{2,5 bis(trifluoromethyl)phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide
- (5.ALPHA.,17.BETA.)-N-(2,5-BIS(TRIFLUOROMETHYL)PHENYL)-3-OXO-4-AZAANDROST-1-ENE-17-CARBOXAMIDE
- (5.alpha.,5 bis(trifluoromethyl)phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide;dutasteride;Avodart;
- (5|_,17|_)-N-[2,5-Bis(trifluoromethyl)phenyl]-3-oxo-4- Aza -androst-1-ene-17-carboxamide
- (5alpha,17beta)-N-[2,5-Bis(trifluoromethyl)phenyl]-3-oxo-4-azaandrost-1-ene-17-carboxamide
- (5alpha,17beta)-N-{2,5-bis(trifluoromethyl)-phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide
- .ALPHA.,.ALPHA.,.ALPHA.,.ALPHA.',.ALPHA.',.ALPHA.'-HEXAFLUORO-3-OXO-4-AZA-5.ALPHA.-ANDROST-1-ENE-17.BETA.-CARBOXY-2',5'-XYLIDIDE
- 1646570-98-0
- 1H-Indeno(5,4-f)quinoline-7-carboxamide, N-(2,5-bis(trifluoromethyl)phenyl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)-
- 1h-indeno[5,4-f]quinolina-7-carboxamida, n-[2,5-bis(trifluorometil)fenil]-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahidro-4a,6a-dimetil-2-oxo-, (4ar,4bs,6as,7s,9as,9bs,11ar)-
- 1H-Indeno[5,4-f]quinoline-7-carboxamide, N-[2,5-bis(trifluoromethyl)phenyl]-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)-; Avodart; Avolve; Dutasteride; GG 745; GI 198745; Veltride; 4-Azaandrost-1-ene-17-carboxamide, N-[2,5-bis(trifluoromethyl)phenyl]-3-oxo-, (5alpha,17beta)-; (5alpha,17beta)-N-[(2,5-Bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5-androst-1-ene-17-carboxamide; GI 198745X; GI 206020X; GW 504051X; GW 418079X; GI 246118X; Dutasteride; GW 403358X; GI 246071X; GW 402839X; GW 402836X
- Avolve,(5alpha,17beta)-N-(2,5-Bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide